📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding XRAY

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Jim Simons Renaissance Technologies LLC	1.57M	$18.2M	0.03%	Mar 2026
Cathie Wood ARK Investment Management	266.7K	$3.1M	0.02%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific ~ Volatile 4 quarters analysed

Q2 2025

Cautious

The new CEO emphasized listening and learning before making changes, and the CFO noted top-line challenges while highlighting margin expansion, reflecting careful optimism without overcommitting.

Q3 2025

Confident Specific

The CEO uses direct, action-oriented language such as 'go deeper, move faster, be bolder' and provides a detailed four-pillar return-to-growth plan with specific initiatives. He acknowledges past shortcomings but expresses strong conviction in the company's potential, stating 'I believe the potential for Dentsply Sirona has never been greater.'

Q4 2025

Confident Specific

Management repeatedly used strong, assertive language such as 'confident', 'strong momentum', 'decisive action', and 'everything at our fingertips', while providing a detailed five-pillar Return-to-Growth plan with specific financial targets (e.g., restructuring leading to $120M annual savings, R&D increase to ~5% of sales). The tone was forward-looking and action-oriented, not vague or defensive.

Q1 2026 latest

Confident Specific

Management repeatedly states they are 'where we expect to be' at this early stage of the Return-to-Growth plan, provides specific actions taken (new distribution deals, product launches, OpEx reduction of $20M) and maintains full-year guidance, signaling confidence despite acknowledging headwinds.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis remains unchanged after this call: the company is in early execution of a 24-month turnaround plan with tangible actions (new distribution, product launches, cost cuts) but no material financial inflection yet. The maintained guidance provides a floor, but the lack of near-term revenue growth (constant currency sales down 4.5% adjusting for one-offs) and continued gross margin pressure keep the thesis in a 'show me' phase. Key metrics to watch next quarter are U.S. dental growth, implant segment improvement, and evidence that the expanded distribution is driving sell-through. The tone is cautiously optimistic but risks from macro and destocking persist, making the stock a wait-and-see until the second half of 2026.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific ~ Volatile 4 quarters Full tone analysis in Intelligence →

📊 MIXED Dentsply Sirona Q1 2026 revenue $880M, adjusts EPS $0.27, maintains full-year outlook.

Revenue & Profitability

First quarter 2026 revenue was $880 million, an as-reported increase of 0.1% over the prior year but a constant currency decline of 6.7%. Adjusted EBITDA margins decreased 430 basis points, driven by a 560 basis point decline in gross profit. Adjusted EPS was $0.27. Operating cash flow was $40 million, up from $7 million in the prior year. The company reduced debt by $79 million, ending the quarter with cash of $190 million and a net debt-to-EBITDA ratio of 3.3 times.

Outlook

Management sees the underlying dental market as stable but is monitoring geopolitical and macro factors closely. External pressures include tariffs, destocking at dealers, and softness in Central Europe and the Middle East. The company is maintaining its full-year 2026 outlook of net sales $3.5 billion–$3.6 billion and adjusted EPS $1.40–$1.50, applying a risk-aware approach given uncertainty.

Growth Drivers

Key growth levers include returning the U.S. to growth through expanded distribution, clinical education, and sales force training. Innovation investments (e.g., Smart View Detect, Reciproc Minima, SureSmile in EMEA) and implant business improvements are priorities. Early traction is seen in EDS APAC (double-digit growth), SureSmile EMEA (11% growth), and Wellspect HealthCare (3.4% constant currency growth). The company is also pursuing DSO partnerships and bundling strategies.

Balance Sheet & CapEx

Capital expenditure guidance was not explicitly provided. The company is advancing its enterprise AI strategy, deploying AI-enabled tools in Q1 with broader rollout planned. Restructuring is on track to deliver approximately $120 million in annual savings, with savings reinvested into R&D, clinical education, and commercial capabilities. Operating expenses were reduced by $20 million in Q1 on a constant currency basis.

Margins

Adjusted EBITDA margins declined 430 basis points year-over-year, driven by a 560 basis point gross margin contraction from tariffs, lower volumes, and negative mix. Operating expenses decreased $20 million on a constant currency basis due to restructuring and cost control, partially offset by higher R&D spending. The CFO expects gross margin to recover at least 300 basis points in Q2/Q3. Full-year margin benefits from restructuring are expected to be more meaningful in the second half.

Key Risks

Key risks include geopolitical and macroeconomic uncertainty, particularly in Central Europe and the Middle East. Tariff impacts are a headwind, and input cost increases from freight and oil are being monitored. Destocking at dealers, especially in Europe, affected EDS volumes. The company also faces potential risks from continued softness in consumer demand and market competition. Management noted no material changes yet but reserved the right to update assumptions.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Q2 2026 revenue declined 4.1% as reported, with flat adjusted EPS and strong cash flow boosted by tariff refunds. The Return-to-Growth plan is progressing, with investments in commercial capabilities and innovation expected to drive improvement, especially in Q4.

Q1 2026 Q1 2026 2026-05-05

Q1 2026 results were in line with expectations, with revenue stable and early progress on cost savings and innovation. The company maintained its full-year outlook, focusing on restructuring, debt reduction, and new product launches, while monitoring macro risks and competitive pressures.

Q4 2025 Q4 2025 2026-02-26

Q4 and full-year 2025 results met expectations, with revenue growth in key segments and margin expansion despite tariff headwinds. The 2026 outlook includes lower sales, higher R&D investment, a dividend cut, and a focus on U.S. growth and operational transformation.

Q3 2025 Q3 2025 2025-11-06

Q3 sales declined 5% as reported, with U.S. sales down sharply but Europe growing modestly. The company revised 2025 guidance downward and is accelerating R&D and operational changes, with a new leadership team and a four-pillar turnaround plan focused on growth and efficiency.

Q2 2025 Q2 2025 2025-08-07

Q2 sales declined 4.9% year-over-year to $936M, but adjusted EBITDA margin rose to 21.1% and EPS grew 6.6%. Leadership transition is underway, with a focus on customer experience, innovation, and operational efficiency. Full-year guidance is maintained despite tariff headwinds.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.